US 11117968
Activatable anti-CTLA-4 antibodies and uses thereof
granted A61KA61K2039/505A61K39/395
Quick answer
US patent 11117968 (Activatable anti-CTLA-4 antibodies and uses thereof) held by CytomX Therapeutics, Inc. expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K39/395, A61P, A61P35/00